Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 2/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 14/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22733691 | 0.93 | ADORA3 (0.45) | PDE4APDE4BPDE4CPDE4DTLR7 | |
| SCHEMBL19378232 | 0.89 | ADORA3 (0.44) | PDE4APDE4BPDE4CPDE4DTLR7 | |
| SCHEMBL19378234 | 0.81 | TLR7 (0.58) | PDE4APDE4BPDE4CPDE4DTLR7 | |
| SCHEMBL28426053 | 0.81 | ADORA3 (0.40) | PDE4APDE4BPDE4CPDE4DTLR7 | |
| SCHEMBL19378209 | 0.81 | ADORA3 (0.44) | PDE4APDE4BPDE4CPDE4DADORA3 | |
| SCHEMBL19378166 | 0.81 | TLR7 (0.42) | TLR7 | |
| SCHEMBL19378160 | 0.81 | ADORA3 (0.48) | PDE4APDE4BPDE4CPDE4DADORA3 | |
| SCHEMBL19378193 | 0.81 | TLR7 (0.43) | PDE4APDE4BPDE4CPDE4DTLR7 | |
| SCHEMBL19378349 | 0.80 | TYMS (0.44) | TLR7ADORA3 | |
| SCHEMBL19378383 | 0.79 | TLR7 (0.44) | TLR7ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11242345-B2 | Sulfonimidoylpurinone compounds and methods of treatment using the same | HOFFMANN-LA ROCHE INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20200109144-A1 | Sulfonimidoylpurinone Compounds | HOFFMANN-LA ROCHE INC. (US) | 2020-04-09 | — | — | US | disclosed |
| US-10399983-B2 | Sulfonimidoylpurinone compounds | HOFFMANN-LA ROCHE INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20170275286-A1 | Novel Sulfonimidoylpurinone Compounds and Derivatives for the Treatment and Prophylaxis of Virus Infection | HOFFMANN-LA ROCHE INC. (US) | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275286-A1 | Novel Sulfonimidoylpurinone Compounds and Derivatives for the Treatment and Prophylaxis of Virus Infection | PRSS1, TPMT, SULT1E1 | PDE4A 3508/4885PDE4B 3777/4885PDE4C 3946/4885 |
| US-20200109144-A1 | Sulfonimidoylpurinone Compounds | NQO1, UGT1A1, SULT1E1 | PDE4A 2566/4885PDE4B 2616/4885PDE4C 2551/4885 |
| US-10399983-B2 | Sulfonimidoylpurinone compounds | NQO1, UGT1A1, SULT1E1 | PDE4A 2566/4885PDE4B 2616/4885PDE4C 2551/4885 |
| US-11242345-B2 | Sulfonimidoylpurinone compounds and methods of treatment using the same | STS, SULT1E1, SULT1A1 | PDE4A 2503/4885PDE4B 2593/4885PDE4C 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.